Merck Statement regarding Role of PNEUMOVAX® 23 (Pneumococcal Vaccine Polyvalent) in Updated ACIP Recommendations for Pneumococcal Vaccination in Adults

13 August, 2014 Merck, known as MSD outside of the United States and Canada, today provided the following statement regarding the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices’ (ACIP’s) updated pneumococcal vaccine recommendations for adults 65 years of age and older. These recommendations call for a two vaccine regimen utilizing a dose of the …

Top 10 Vaccines in 2013

  #10 – Pneumovax Pneumococcal infection 2013 – $653 million 2012 – $580 million Marketed by Merck and Sanofi Pasteur MSD #9 – RotaTeq Rotaviral gastroenteritis 2013 – $691 million 2012 – $648 million Marketed by Merck and Sanofi Pasteur MSD #8 – Zostavax Herpes Zoster (Shingles) 2013 – $826 million 2012 – $ N/A Marketed by Merck and Sanofi Pasteur MSD #7 – Hepatitis vaccine franchise Hepatitis A, Hepatitis B 2013 – $984 million 2012 …